Nantes, France – June 15, 2023, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that the latest scientific data has been selected for oral or poster presentations at several upcoming international conferences: at the Antibody Engineering conference & Therapeutics Europe 2023 in Amsterdam (June 7), FOCIS 2023 Annual Meeting (June 20-23), 4th Annual Cytokine-Based Drug Development Summit 2023 (June 27-29) and 3rd Annual Tumor Myeloid-directed Therapies Summit 2023 (July 18-20), these last three conferences being held in Boston. These presentations focus on the latest preclinical data from the BiCKI®-IL7 (bifunctional targeting PD1 and IL-7) and CLEC-1 (new myeloid immune checkpoint) programs in immuno-oncology, and OSE-230 (first monoclonal antibody pro -resolving) in chronic inflammation.